{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:42:28Z","timestamp":1789123348914,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s11102-024-01479-9","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T11:32:33Z","timestamp":1735212753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9241-2392","authenticated-orcid":false,"given":"Sabrina","family":"Chiloiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Giampietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Giamb\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Costanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Paolo","family":"Mattogno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liverana","family":"Lauretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinda","family":"Calandrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Gaudino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Rindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Olivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7438-0734","authenticated-orcid":false,"given":"Francesco","family":"Doglietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Pontecorvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giustina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,26]]},"reference":[{"key":"1479_CR1","doi-asserted-by":"publisher","unstructured":"Melmed S, Pituitary-Tumor, Endocrinopathies (2020) N Engl J Med 382(10):937\u2013950. https:\/\/doi.org\/10.1056\/NEJMra1810772","DOI":"10.1056\/NEJMra1810772"},{"issue":"1","key":"1479_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","volume":"5","author":"A Colao","year":"2019","unstructured":"Colao A, Grasso LFS, Giustina A et al (2019) Acromegaly. Nat Rev Dis Primers 5(1):20. https:\/\/doi.org\/10.1038\/s41572-019-0071-6","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"1479_CR3","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","volume":"43","author":"S Melmed","year":"2022","unstructured":"Melmed S, Kaiser UB, Lopes MB et al (2022) Clinical Biology of the Pituitary Adenoma. Endocr Rev 43(6):1003\u20131037. https:\/\/doi.org\/10.1210\/endrev\/bnac010","journal-title":"Endocr Rev"},{"issue":"15","key":"1479_CR4","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/S0002-9149(99)80721-8","volume":"75","author":"A Giustina","year":"1995","unstructured":"Giustina A, Boni E, Romanelli G, Grossi V, Giustina G (1995) Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am J Cardiol 75(15):1042\u20131047. https:\/\/doi.org\/10.1016\/S0002-9149(99)80721-8","journal-title":"Am J Cardiol"},{"issue":"4","key":"1479_CR5","doi-asserted-by":"publisher","first-page":"e937","DOI":"10.1210\/clinem\/dgz096","volume":"105","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkan A, Beckers A et al (2020) A Consensus on the diagnosis and treatment of Acromegaly comorbidities: an update. J Clin Endocrinol Metab 105(4):e937\u2013e946. https:\/\/doi.org\/10.1210\/clinem\/dgz096","journal-title":"J Clin Endocrinol Metab"},{"key":"1479_CR6","doi-asserted-by":"publisher","unstructured":"Arosio M, Sciannameo V, Contarino A et al (2024) Disease control of acromegaly does not prevent excess mortality in the long term: results of a nationwide survey in Italy. J Endocrinol Invest Published Online January 12. https:\/\/doi.org\/10.1007\/s40618-023-02257-3","DOI":"10.1007\/s40618-023-02257-3"},{"key":"1479_CR7","doi-asserted-by":"publisher","unstructured":"Orme S, McNally R, James PW et al (2024) Increased mortality in acromegaly is due to vascular and respiratory disease and is normalised by control of GH levels\u2014A retrospective analysis from the UK Acromegaly Register 1970\u20132016. Published Online April 23 Clin Endocrinol (Oxf). https:\/\/doi.org\/10.1111\/cen.15060","DOI":"10.1111\/cen.15060"},{"issue":"1","key":"1479_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Biermasz N, Casanueva FF et al (2024) Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27(1):7\u201322. https:\/\/doi.org\/10.1007\/s11102-023-01360-1","journal-title":"Pituitary"},{"issue":"4","key":"1479_CR9","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","volume":"21","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkhoudarian G, Beckers A et al (2020) Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord 21(4):667\u2013678. https:\/\/doi.org\/10.1007\/s11154-020-09588-z","journal-title":"Rev Endocr Metab Disord"},{"issue":"5","key":"1479_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","volume":"20","author":"FF Casanueva","year":"2017","unstructured":"Casanueva FF, Barkan AL, Buchfelder M et al (2017) Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): a Pituitary Society Statement. Pituitary 20(5):489\u2013498. https:\/\/doi.org\/10.1007\/s11102-017-0838-2","journal-title":"Pituitary"},{"issue":"5","key":"1479_CR11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11102-023-01345-0","volume":"26","author":"A Giustina","year":"2023","unstructured":"Giustina A, Uygur MM, Frara S et al (2023) Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers. Pituitary 26(5):583\u2013596. https:\/\/doi.org\/10.1007\/s11102-023-01345-0","journal-title":"Pituitary"},{"key":"1479_CR12","doi-asserted-by":"publisher","unstructured":"Giustina A, Uygur MM, Frara S et al (2024) Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE). Pituit Published Online June 4. https:\/\/doi.org\/10.1007\/s11102-024-01397-w","DOI":"10.1007\/s11102-024-01397-w"},{"issue":"5","key":"1479_CR13","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s11102-019-00977-5","volume":"22","author":"A Giustina","year":"2019","unstructured":"Giustina A, Bronstein MD, Chanson P et al (2019) Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT\u00ae validation study. Pituitary 22(5):476\u2013487. https:\/\/doi.org\/10.1007\/s11102-019-00977-5","journal-title":"Pituitary"},{"issue":"2","key":"1479_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s12020-023-03317-7","volume":"80","author":"A Giustina","year":"2023","unstructured":"Giustina A, di Filippo L, Uygur MM, Frara S (2023) Modern approach to resistant acromegaly. Endocrine 80(2):303\u2013307. https:\/\/doi.org\/10.1007\/s12020-023-03317-7","journal-title":"Endocrine"},{"key":"1479_CR15","doi-asserted-by":"publisher","unstructured":"Chiloiro S, Moroni R, Giampietro A et al (2023) The Multibiomarker Acro-TIME score predicts fg-SRLs response: preliminary results of a retrospective acromegaly cohort. J Clin Endocrinol Metab Published Online November 17. https:\/\/doi.org\/10.1210\/clinem\/dgad673","DOI":"10.1210\/clinem\/dgad673"},{"key":"1479_CR16","doi-asserted-by":"publisher","unstructured":"Chiloiro S, Bianchi A, Giampietro A, Pontecorvi A, Raverot G, Marinis L, De (2022) Second line treatment of acromegaly: Pasireotide or Pegvisomant? Best Pract Res Clin Endocrinol Metab. https:\/\/doi.org\/10.1016\/j.beem.2022.101684","DOI":"10.1016\/j.beem.2022.101684"},{"issue":"2","key":"1479_CR17","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1210\/clinem\/dgab726","volume":"107","author":"MR Gadelha","year":"2022","unstructured":"Gadelha MR, Wildemberg LE, Kasuki L (2022) The future of somatostatin receptor ligands in Acromegaly. J Clin Endocrinol Metab 107(2):297\u2013308. https:\/\/doi.org\/10.1210\/clinem\/dgab726","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1479_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nrendo.2014.21","volume":"10","author":"A Giustina","year":"2014","unstructured":"Giustina A, Chanson P, Kleinberg D et al (2014) Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 10(4):243\u2013248. https:\/\/doi.org\/10.1038\/nrendo.2014.21","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"1479_CR19","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3390\/medicina58060794","volume":"58","author":"A Brunetti","year":"2022","unstructured":"Brunetti A, Antonini S, Saladino A, Lavezzi E, Zampetti B, Cozzi R (2022) Clinical Management of Acromegaly: therapeutic frontiers and new perspectives for somatostatin receptor ligands (SRLs). Med (B Aires) 58(6):794. https:\/\/doi.org\/10.3390\/medicina58060794","journal-title":"Med (B Aires)"},{"issue":"8","key":"1479_CR20","doi-asserted-by":"publisher","first-page":"102924","DOI":"10.1016\/j.arcmed.2023.102924","volume":"54","author":"M Marques-Pamies","year":"2023","unstructured":"Marques-Pamies M, Gil J, Jord\u00e0 M, Puig-Domingo M (2023) Predictors of response to treatment with first-generation somatostatin receptor ligands in patients with acromegaly. Arch Med Res 54(8):102924. https:\/\/doi.org\/10.1016\/j.arcmed.2023.102924","journal-title":"Arch Med Res"},{"key":"1479_CR21","doi-asserted-by":"publisher","unstructured":"Remba-Shapiro I, Nachtigall LB Treatment of acromegaly with oral octreotide. Best Pract Res Clin Endocrinol Metab Published Online Febr 2024:101888. https:\/\/doi.org\/10.1016\/j.beem.2024.101888","DOI":"10.1016\/j.beem.2024.101888"},{"issue":"6","key":"1479_CR22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1530\/EJE-22-0220","volume":"187","author":"SL Samson","year":"2022","unstructured":"Samson SL, Nachtigall LB, Fleseriu M et al (2022) Durable biochemical response and safety with oral octreotide capsules in acromegaly. Eur J Endocrinol 187(6):733\u2013741. https:\/\/doi.org\/10.1530\/EJE-22-0220","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"1479_CR23","doi-asserted-by":"publisher","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","volume":"105","author":"SL Samson","year":"2020","unstructured":"Samson SL, Nachtigall LB, Fleseriu M et al (2020) Maintenance of Acromegaly Control in patients switching from Injectable somatostatin receptor ligands to oral Octreotide. J Clin Endocrinol Metab 105(10):e3785\u2013e3797. https:\/\/doi.org\/10.1210\/clinem\/dgaa526","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1479_CR24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/BF03349183","volume":"29","author":"M Gola","year":"2006","unstructured":"Gola M, Bonadonna S, Mazziotti G, Amato G, Giustina A (2006) Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest 29(1):86\u201393. https:\/\/doi.org\/10.1007\/BF03349183","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"1479_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/17446651.2023.2293107","volume":"19","author":"L Kasuki","year":"2024","unstructured":"Kasuki L, Lamback E, Antunes X, Gadelha MR (2024) Biomarkers of response to treatment in acromegaly. Expert Rev Endocrinol Metab 19(1):71\u201380. https:\/\/doi.org\/10.1080\/17446651.2023.2293107","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"2","key":"1479_CR26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1530\/EJE-09-0372","volume":"161","author":"A Giustina","year":"2009","unstructured":"Giustina A, Bonadonna S, Bugari G et al (2009) High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 161(2):331\u2013338. https:\/\/doi.org\/10.1530\/EJE-09-0372","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"1479_CR27","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1210\/jc.2017-00142","volume":"102","author":"A Giustina","year":"2017","unstructured":"Giustina A, Mazziotti G, Cannav\u00f2 S et al (2017) High-dose and High-Frequency Lanreotide Autogel in Acromegaly: a Randomized, Multicenter Study. J Clin Endocrinol Metab 102(7):2454\u20132464. https:\/\/doi.org\/10.1210\/jc.2017-00142","journal-title":"J Clin Endocrinol Metab"},{"key":"1479_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/bs.pmbts.2015.10.015","volume":"138","author":"S Frara","year":"2016","unstructured":"Frara S, Maffezzoni F, Mazziotti G, Giustina A (2016) The Modern Criteria for Medical Management of Acromegaly. Prog Mol Biol Transl Sci 138:63\u201383. https:\/\/doi.org\/10.1016\/bs.pmbts.2015.10.015","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"12","key":"1479_CR29","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.3390\/cancers11121936","volume":"11","author":"S Serioli","year":"2019","unstructured":"Serioli S, Doglietto F, Fiorindi A et al (2019) Pituitary adenomas and invasiveness from Anatomo-Surgical, Radiological, and histological perspectives: a systematic literature review. Cancers (Basel) 11(12):1936. https:\/\/doi.org\/10.3390\/cancers11121936","journal-title":"Cancers (Basel)"},{"issue":"4","key":"1479_CR30","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1227\/00006123-199310000-00008","volume":"33","author":"E Knosp","year":"1993","unstructured":"Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary Adenomas with Invasion of the cavernous Sinus Space. Neurosurgery 33(4):610\u2013618. https:\/\/doi.org\/10.1227\/00006123-199310000-00008","journal-title":"Neurosurgery"},{"issue":"3","key":"1479_CR31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11102-013-0500-6","volume":"17","author":"S Chiloiro","year":"2014","unstructured":"Chiloiro S, Bianchi A, Doglietto F et al (2014) Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review. Pituitary 17(3):267\u2013276. https:\/\/doi.org\/10.1007\/s11102-013-0500-6","journal-title":"Pituitary"},{"issue":"3","key":"1479_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1530\/EJE-15-0586","volume":"174","author":"A Coli","year":"2016","unstructured":"Coli A, Asa SL, Fadda G et al (2016) Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients. Eur J Endocrinol 174(3):307\u2013314. https:\/\/doi.org\/10.1530\/EJE-15-0586","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1479_CR33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","volume":"77","author":"A Heck","year":"2012","unstructured":"Heck A, Ringstad G, Fougner SL et al (2012) Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol (Oxf) 77(1):72\u201378. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04286.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"1479_CR34","doi-asserted-by":"publisher","first-page":"101892","DOI":"10.1016\/j.beem.2024.101892","volume":"38","author":"C Ram\u00edrez-Renter\u00eda","year":"2024","unstructured":"Ram\u00edrez-Renter\u00eda C, Hern\u00e1ndez-Ram\u00edrez LC (2024) Genetic diagnosis in acromegaly and gigantism: from research to clinical practice. Best Pract Res Clin Endocrinol Metab 38(3):101892. https:\/\/doi.org\/10.1016\/j.beem.2024.101892","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"1479_CR35","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1530\/EJE-12-0763","volume":"168","author":"T Cuny","year":"2013","unstructured":"Cuny T, Pertuit M, Sahnoun-Fathallah M et al (2013) Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don\u2019t forget MEN1 genetic analysis. Eur J Endocrinol 168(4):533\u2013541. https:\/\/doi.org\/10.1530\/EJE-12-0763","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1479_CR36","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1210\/jcem.85.2.6363","volume":"85","author":"A Giustina","year":"2000","unstructured":"Giustina A, Barkan A, Casanueva FF et al (2000) Criteria for cure of Acromegaly: a Consensus Statement. J Clin Endocrinol Metab 85(2):526\u2013529. https:\/\/doi.org\/10.1210\/jcem.85.2.6363","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1479_CR37","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1210\/jc.2009-2670","volume":"95","author":"A Giustina","year":"2010","unstructured":"Giustina A, Chanson P, Bronstein MD et al (2010) A Consensus on Criteria for Cure of Acromegaly. J Clin Endocrinol Metab 95(7):3141\u20133148. https:\/\/doi.org\/10.1210\/jc.2009-2670","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1479_CR38","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s11102-012-0420-x","volume":"16","author":"S Melmed","year":"2013","unstructured":"Melmed S, Casanueva FF, Klibanski A et al (2013) A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16(3):294\u2013302. https:\/\/doi.org\/10.1007\/s11102-012-0420-x","journal-title":"Pituitary"},{"key":"1479_CR39","doi-asserted-by":"publisher","unstructured":"Tomasik A, Stelmachowska-Bana\u015b M, Maksymowicz M et al (2022) Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly. Front Endocrinol (Lausanne) 13. https:\/\/doi.org\/10.3389\/fendo.2022.957301","DOI":"10.3389\/fendo.2022.957301"},{"issue":"1","key":"1479_CR40","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/cen.14750","volume":"98","author":"J Dal","year":"2023","unstructured":"Dal J, Rosendal C, Karmisholt J et al (2023) Sex difference in patients with controlled acromegaly\u2014A multicentre survey. Clin Endocrinol (Oxf) 98(1):74\u201381. https:\/\/doi.org\/10.1111\/cen.14750","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"1479_CR41","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s11102-019-01020-3","volume":"23","author":"S Petersenn","year":"2020","unstructured":"Petersenn S, Houchard A, Sert C, Caron PJ (2020) Predictive factors for responses to primary medical treatment with lanreotide autogel 120\u00a0mg in acromegaly: post hoc analyses from the PRIMARYS study. Pituitary 23(2):171\u2013181. https:\/\/doi.org\/10.1007\/s11102-019-01020-3","journal-title":"Pituitary"},{"issue":"3","key":"1479_CR42","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.eprac.2021.12.017","volume":"28","author":"DST Lim","year":"2022","unstructured":"Lim DST, Fleseriu M (2022) Personalized Medical treatment of patients with acromegaly: a review. Endocr Pract 28(3):321\u2013332. https:\/\/doi.org\/10.1016\/j.eprac.2021.12.017","journal-title":"Endocr Pract"},{"key":"1479_CR43","unstructured":"https:\/\/medicinali.aifa.gov.itit#itdettaglio0000024467"},{"issue":"3","key":"1479_CR44","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s12020-023-03430-7","volume":"81","author":"M Solak","year":"2023","unstructured":"Solak M, Kraljevi\u0107 I, Popovac H et al (2023) Medical treatment of acromegaly\u2014experience from the Croatian acromegaly registry. Endocrine 81(3):555\u2013561. https:\/\/doi.org\/10.1007\/s12020-023-03430-7","journal-title":"Endocrine"},{"issue":"1","key":"1479_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/jcm12010025","volume":"12","author":"AM Berton","year":"2022","unstructured":"Berton AM, Prencipe N, Bertero L et al (2022) Resistance to somatostatin analogs in Italian acromegaly patients: the MISS Study. J Clin Med 12(1):25. https:\/\/doi.org\/10.3390\/jcm12010025","journal-title":"J Clin Med"},{"issue":"4","key":"1479_CR46","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1210\/clinem\/dgac610","volume":"108","author":"CGB Herkenhoff","year":"2023","unstructured":"Herkenhoff CGB, Trarbach EB, Batista RL et al (2023) Survivin: a potential marker of resistance to somatostatin receptor ligands. J Clin Endocrinol Metab 108(4):876\u2013887. https:\/\/doi.org\/10.1210\/clinem\/dgac610","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1479_CR47","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1210\/jc.2013-3318","volume":"99","author":"PJ Caron","year":"2014","unstructured":"Caron PJ, Bevan JS, Petersenn S et al (2014) Tumor shrinkage with lanreotide autogel 120\u00a0mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab 99(4):1282\u20131290. https:\/\/doi.org\/10.1210\/jc.2013-3318","journal-title":"J Clin Endocrinol Metab"},{"key":"1479_CR48","doi-asserted-by":"publisher","unstructured":"Biagetti B, Iglesias P, Villar-Taibo R et al (2022) Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain. Front Endocrinol (Lausanne) 13. https:\/\/doi.org\/10.3389\/fendo.2022.984877","DOI":"10.3389\/fendo.2022.984877"},{"issue":"1","key":"1479_CR49","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s12020-021-02766-2","volume":"74","author":"KZB Manosso","year":"2021","unstructured":"Manosso KZB, Sampaio CL, Kasuki L, Antunes X, Gadelha MR, Boguszewski CL (2021) GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil. Endocrine 74(1):146\u2013154. https:\/\/doi.org\/10.1007\/s12020-021-02766-2","journal-title":"Endocrine"},{"key":"1479_CR50","doi-asserted-by":"publisher","unstructured":"Nista F, Corica G, Castelletti L et al (2021) Clinical and radiological predictors of biochemical response to first-line treatment with somatostatin receptor ligands in Acromegaly: a real-life perspective. Front Endocrinol (Lausanne) 12. https:\/\/doi.org\/10.3389\/fendo.2021.677919","DOI":"10.3389\/fendo.2021.677919"},{"issue":"6","key":"1479_CR51","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1530\/ERC-18-0565","volume":"27","author":"M Puig-Domingo","year":"2020","unstructured":"Puig-Domingo M, Gil J, Sampedro-Nu\u00f1ez M et al (2020) Molecular profiling for acromegaly treatment: a validation study. Endocr Relat Cancer 27(6):375\u2013389. https:\/\/doi.org\/10.1530\/ERC-18-0565","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"1479_CR52","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11102-018-0867-5","volume":"21","author":"H Alquraini","year":"2018","unstructured":"Alquraini H, del Pilar Schneider M, Mirakhur B, Barkan A (2018) Biochemical efficacy of long-acting Lanreotide depot\/Autogel in patients with acromegaly na\u00efve to somatostatin-receptor ligands: analysis of three multicenter clinical trials. Pituitary 21(3):283\u2013289. https:\/\/doi.org\/10.1007\/s11102-018-0867-5","journal-title":"Pituitary"},{"issue":"10","key":"1479_CR53","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40618-014-0146-x","volume":"37","author":"A Giustina","year":"2014","unstructured":"Giustina A, Ambrosio MR, Beck Peccoz P et al (2014) Use of Pegvisomant in Acromegaly. An Italian Society of Endocrinology guideline. J Endocrinol Invest 37(10):1017\u20131030. https:\/\/doi.org\/10.1007\/s40618-014-0146-x","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"1479_CR54","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40618-017-0614-1","volume":"40","author":"A Giustina","year":"2017","unstructured":"Giustina A, Arnaldi G, Bogazzi F et al (2017) Pegvisomant in acromegaly: an update. J Endocrinol Invest 40(6):577\u2013589. https:\/\/doi.org\/10.1007\/s40618-017-0614-1","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"1479_CR55","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/14737167.2019.1610396","volume":"20","author":"C Peral","year":"2020","unstructured":"Peral C, Cordido F, Gimeno-Ballester V et al (2020) Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain. Expert Rev Pharmacoecon Outcomes Res 20(1):105\u2013114. https:\/\/doi.org\/10.1080\/14737167.2019.1610396","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"7","key":"1479_CR56","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/jcm10071377","volume":"10","author":"A Bogus\u0142awska","year":"2021","unstructured":"Bogus\u0142awska A, Korbonits M (2021) Genetics of Acromegaly and Gigantism. J Clin Med 10(7):1377. https:\/\/doi.org\/10.3390\/jcm10071377","journal-title":"J Clin Med"},{"issue":"5","key":"1479_CR57","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1210\/jc.2008-2421","volume":"94","author":"S Melmed","year":"2009","unstructured":"Melmed S, Colao A, Barkan A et al (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94(5):1509\u20131517. https:\/\/doi.org\/10.1210\/jc.2008-2421","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1479_CR58","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1046\/j.1365-2265.2003.01900.x","volume":"60","author":"JA Takahashi","year":"2004","unstructured":"Takahashi JA, Shimatsu A, Nakao K, Hashimoto N (2004) Early postoperative indicators of late outcome in acromegalic patients. Clin Endocrinol (Oxf) 60(3):366\u2013374. https:\/\/doi.org\/10.1046\/j.1365-2265.2003.01900.x","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01479-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-024-01479-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01479-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T14:33:30Z","timestamp":1741444410000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-024-01479-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1479"],"URL":"https:\/\/doi.org\/10.1007\/s11102-024-01479-9","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,26]]},"assertion":[{"value":"13 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in the study were in accordance with the ethical standards of the institutional review board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Institutional Review Board of the University Hospital \u201cFondazione Policlinico Universitario A. Gemelli IRCCS\u201d in Rome, Italy (Protocol ID: 5132).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All the authors declare no conflict of interest that could be perceived as prejudicing the impartiality of this paper. Sabrina Chiloiro recipient of Research grant to Institution from Ipsen, Pfizer, and Recordati. Andrea Giustina consultant for Amolyt, Ipsen, Pfizer, and Recordati and is Editor of Pituitary.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}